Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Breast 1

Conditions

Stomach Neoplasms 2Recurrence 1Neoplasm Metastasis 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × margetuximab × Clear all
NCT04082364 2025-06-08

MAHOGANY

MacroGenics

Phase 2/3 Completed
82 enrolled 22 charts
Gastrointestinal

Stomach Neoplasms

NCT02492711 2025-03-17

SOPHIA

MacroGenics

Phase 3 Completed
624 enrolled 17 charts 1 FDA
Tumor-Agnostic

Neoplasm Metastasis

NCT02689284 2025-03-17

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

MacroGenics

Phase 1/2 Completed
95 enrolled 26 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT01828021 2025-03-13

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

MacroGenics

Phase 2 Completed
25 enrolled 8 charts
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡